Paronychia Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Acute Paronychia and Chronic Paronychia); By Product; By End User; By Region; Segment Forecast, 2023-2032

Paronychia Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Acute Paronychia and Chronic Paronychia); By Product; By End User; By Region; Segment Forecast, 2023-2032

The global paronychia treatment market size is expected to reach USD 933.78 million by 2032, according to a new study by Polaris Market Research. The report “Paronychia Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Acute Paronychia and Chronic Paronychia); By Product; By End Use; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of paronychia worldwide and improved awareness about the paronychia among both the healthcare professionals and general population coupled with the availability of a range of treatment options and ongoing research and development activities focused on introducing new effective treatment options, are major prominent factors propelling the market growth. Additionally, several favorable regulatory policies that supports the development and approval of safe and effective treatments, while encouraging the investment and innovations in the market, is further likely to have a positive impact on market growth.

For instance, in May 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson, said that the US Food and Drug Administration, has approved the RYBREVANT™, mainly developed for the treatment of patients with musculoskeletal pain, paronychia, nausea, fatigue and edema.

With the growing emphasis on raising awareness about paronychia among healthcare professionals and the general population across the world, several government and private healthcare institutions are undertaking various educational campaigns, awareness programs, and online resources to make people more aware about the availability of the paronychia treatment options, the demand and adoption of these treatments have gained significant popularity and traction.

Moreover, the rising incorporation of telemedicine and digital health technology across wide range of medical specialties including dermatology along with the surging integration of telemedicine platforms, which enables remote consultations, diagnosis, and follow-up care for patients, especially in regions with limited access to dermatological specialists, have also been the key factor influencing the market growth. Beside this, there has been an increasing focus on preventive measures and lifestyle modifications to reduce the risk of paronychia, that positively contributes to the implementation on these treatment options.

Paronychia Treatment Market Report Highlights

Acute paronychia segment accounted for highest market share in 2022, which is mainly driven by growing number of paronychia cases because of higher penetration for poor nail hygiene and trauma to nail

Mupirocin ointment segment held the maximum market revenue share in 2022, mainly due to its widespread availability in different formulations and high adoption among healthcare professionals

Dermatology centers segment is expected to grow at highest growth rate over the coming years, owing to increasing number of dermatology centers worldwide and incorporation of advanced technologies

North America region held largest share in 2022, on account of presence of developed healthcare infrastructure and rising awareness about the treatment availability for paronychia

The global key market players include Teva Pharmaceutical Industries, Eli Lilly Company, Fougera Pharmaceuticals, Johnson & Johnson Services, Bayer AG, Pfizer Inc., and Sandoz International

Polaris Market Research has segmented the paronychia treatment market report based on type, product, end user, and region:

Paronychia Treatment, Type Outlook (Revenue - USD Million, 2023 - 2032)

Acute Paronychia

Chronic Paronychia

Paronychia Treatment, Product Outlook (Revenue - USD Million, 2023 - 2032)

Mupirocin Ointment

Fusidic Acid Ointment

Gentamicin Ointment

Dicloxacillin

Paronychia Treatment, End User Outlook (Revenue - USD Million, 2023 - 2032)

Hospitals & Clinics

Dermatology Centers

Paronychia Treatment, Regional Outlook (Revenue - USD Million, 2023 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa